A Double-Blinded, Placebo-Controlled, Randomized Phase II Study of Enzalutamide With or Without the PI3 Kinase/mTOR Inhibitor LY3023414 in Men with Metastatic Castration Resistant Prostate Cancer - Regional Cancer Care Associates LLC

Clinical Trials

A Double-Blinded, Placebo-Controlled, Randomized Phase II Study of Enzalutamide With or Without the PI3 Kinase/mTOR Inhibitor LY3023414 in Men with Metastatic Castration Resistant Prostate Cancer

Type of Cancer
Genito-Urinary
Locations
Hackensack
Sponsor
Eli Lilly
Protocol Number
I6A-MC-CBBD (GU 115)
Cancer Diagnosis
To Learn More Call
201-510-0910